A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | -3.5M | -3.5M | -3.5M | -1.3M |
| EPS | $-0.29 | $-0.29 | $-0.00 | $-0.00 |
| Free Cash Flow | -3.3M | -3.3M | -2.4M | -1.2M |
| ROIC | -145.4% | -55.0% | -55.2% | -354.2% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 1.50 | 0.32 | 0.06 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -3.1M | -3.1M | -3.0M | -1.6M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -196.4% | -196.4% | -96.1% | -187.0% |
| Shares Outstanding | 12M | 12M | 1,217M | 944M |
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | -778K | -1.3M | -1.3M | -1.3M |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -1.6M | -3.0M | -3.1M | -3.1M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -1.3M | -3.5M | -3.5M | -3.5M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | N/M | -55.2% | -55.0% | -145.4% |
| ROE | -187.0% | -96.1% | -196.4% | -196.4% |
| ROA | -43.9% | -35.9% | -38.7% | -38.7% |
| Cash Flow | ||||
| Op. Cash Flow | -1.2M | -2.4M | -3.3M | -3.3M |
| Free Cash Flow | -1.2M | -2.4M | -3.3M | -3.3M |
| Owner Earnings | -1.3M | -2.5M | -3.3M | -3.3M |
| CapEx | 0 | 11K | 0 | 0 |
| Maint. CapEx | 76K | 32K | 34K | 34K |
| Growth CapEx | N/A | 0 | N/A | 0 |
| D&A | 76K | 32K | 34K | 34K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 31K | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -359K | 559K | 2.6M | -125K |
| Cash & Equiv. | 400K | 616K | 125K | 125K |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.06 | 0.32 | 1.50 | 0.00 |
| Interest Coverage | -512.6 | -13.2 | -4.3 | -4.3 |
| Equity | 715K | 3.7M | 1.8M | 1.8M |
| Total Assets | 3.0M | 9.9M | 9.1M | 9.1M |
| Total Liabilities | 369K | 6.2M | 7.3M | 7.3M |
| Intangibles | 0 | 0 | 0 | 0 |
| Retained Earnings | 0 | 0 | 0 | 0 |
| Working Capital | 674K | 4.8M | 4.3M | 4.3M |
| Current Assets | 1.0M | 9.8M | 8.9M | 8.9M |
| Current Liabilities | 327K | 5.0M | 4.7M | 4.7M |
| Per Share Data | ||||
| EPS | -0.00 | -0.00 | -0.29 | -0.29 |
| Owner EPS | -0.00 | -0.00 | -0.27 | -0.27 |
| Book Value | 0.00 | 0.00 | 0.15 | 0.15 |
| Cash Flow/Share | -0.00 | -0.00 | -0.29 | -0.29 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 944.4M | 1.2B | 12.2M | 12.2M |
| Valuation | ||||
| P/E Ratio | N/A | -21.9 | -0.1 | -0.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 21.0 | 0.2 | 0.6 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -3.1% | -1084.6% | -326.7% |
| Market Cap | 0 | 78M | 305K | 1.0M |
| Avg. Price | 0.00 | 0.06 | 0.04 | 0.08 |
| Year-End Price | 0.00 | 0.06 | 0.03 | 0.08 |
Pharma Equity Group A/S passes 0 of 9 quality checks, indicating weak fundamentals.
Pharma Equity Group A/S (PEG-CO) has a 5-year average return on invested capital (ROIC) of -55.1%. This is below average and may indicate limited pricing power.
Pharma Equity Group A/S (PEG-CO) has a market capitalization of $1M. It is classified as a small-cap stock.
Pharma Equity Group A/S (PEG-CO) does not currently pay a regular dividend.
Pharma Equity Group A/S (PEG-CO) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Pharma Equity Group A/S (PEG-CO) has a debt-to-equity ratio of 1.50. This indicates moderate leverage.
Pharma Equity Group A/S (PEG-CO) reported earnings per share (EPS) of $-0.29 in its most recent fiscal year.
Pharma Equity Group A/S (PEG-CO) has a return on equity (ROE) of -196.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Pharma Equity Group A/S (PEG-CO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pharma Equity Group A/S (PEG-CO) has a book value per share of $0.15, based on its most recent annual SEC filing.
No recent items.